Tags

Type your tag names separated by a space and hit enter

Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.
Arch Pharm Res. 2011 Jan; 34(1):51-7.AP

Abstract

The objective of the study was enhancement of dissolution of poorly soluble carvedilol by solid dispersions (SDs) with Gelucire 50/13 using solvent evaporation method. The solubility of carvedilol showed linear increase with increasing concentrations of Gelucire indicating A(L) type solubility diagrams. SDs characterized for physicochemical characteristics using differential scanning calorimetry and X-ray diffractometry revealed transformation of crystalline form of drug to amorphous form which was confirmed by scanning electron micrographs. Further fourier transform infrared spectroscopy results suggested there is no drug carrier interaction. From the dissolution parameters such as mean dissolution time, dissolution efficiency and drug release rate, improved dissolution characteristics for SDs were observed compared with physical mixture and pure drug. Thus SDs of carvedilol in Gelucire 50/13 showed enhanced solubility and dissolution rate compared to pure drug.

Authors+Show Affiliations

Department of Pharmaceutics and Industrial Pharmacy, St. Peter's Institute of Pharmaceutical Sciences, Vidyanagar, Warangal, AP, India.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21468915

Citation

Potluri, Raja Hemanth Kumar, et al. "Solubility Enhancement and Physicochemical Characterization of Carvedilol Solid Dispersion With Gelucire 50/13." Archives of Pharmacal Research, vol. 34, no. 1, 2011, pp. 51-7.
Potluri RH, Bandari S, Jukanti R, et al. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Arch Pharm Res. 2011;34(1):51-7.
Potluri, R. H., Bandari, S., Jukanti, R., & Veerareddy, P. R. (2011). Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Archives of Pharmacal Research, 34(1), 51-7. https://doi.org/10.1007/s12272-011-0106-3
Potluri RH, et al. Solubility Enhancement and Physicochemical Characterization of Carvedilol Solid Dispersion With Gelucire 50/13. Arch Pharm Res. 2011;34(1):51-7. PubMed PMID: 21468915.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. AU - Potluri,Raja Hemanth Kumar, AU - Bandari,Suresh, AU - Jukanti,Raju, AU - Veerareddy,Prabhakar Reddy, Y1 - 2011/04/06/ PY - 2010/03/05/received PY - 2010/07/01/accepted PY - 2010/06/15/revised PY - 2011/4/7/entrez PY - 2011/4/7/pubmed PY - 2011/7/27/medline SP - 51 EP - 7 JF - Archives of pharmacal research JO - Arch Pharm Res VL - 34 IS - 1 N2 - The objective of the study was enhancement of dissolution of poorly soluble carvedilol by solid dispersions (SDs) with Gelucire 50/13 using solvent evaporation method. The solubility of carvedilol showed linear increase with increasing concentrations of Gelucire indicating A(L) type solubility diagrams. SDs characterized for physicochemical characteristics using differential scanning calorimetry and X-ray diffractometry revealed transformation of crystalline form of drug to amorphous form which was confirmed by scanning electron micrographs. Further fourier transform infrared spectroscopy results suggested there is no drug carrier interaction. From the dissolution parameters such as mean dissolution time, dissolution efficiency and drug release rate, improved dissolution characteristics for SDs were observed compared with physical mixture and pure drug. Thus SDs of carvedilol in Gelucire 50/13 showed enhanced solubility and dissolution rate compared to pure drug. SN - 0253-6269 UR - https://www.unboundmedicine.com/medline/citation/21468915/Solubility_enhancement_and_physicochemical_characterization_of_carvedilol_solid_dispersion_with_Gelucire_50/13_ L2 - https://dx.doi.org/10.1007/s12272-011-0106-3 DB - PRIME DP - Unbound Medicine ER -